API 192
Alternative Names: API-192Latest Information Update: 14 Jun 2024
At a glance
- Originator Appia Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Haematopoietic stem cells therapies; Immunotherapies; NKT cell therapies
- Mechanism of Action Immunologic cytotoxicity; Interleukin 15 replacements; Natural killer T cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical studies in Haematological malignancies in presented at the (full name of conference 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 09 Dec 2023 Pharmacodynamics and immunogenicity data from a preclinical study in Haematological malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 07 Dec 2023 Appia Bio has patent protection for its ACUA platform (Appia Bio website; December 2023)